Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 5
2015 5
2016 7
2017 8
2018 6
2019 9
2020 6
Text availability
Article attribute
Article type
Publication date

Search Results

41 results
Results by year
Filters applied: . Clear all
Page 1
CIMAvax-EGF, a therapeutic non-small cell lung cancer vaccine.
Tagliamento M, Rijavec E, Barletta G, Biello F, Rossi G, Grossi F, Genova C. Tagliamento M, et al. Among authors: biello f. Expert Opin Biol Ther. 2018 Jul;18(7):829-835. doi: 10.1080/14712598.2018.1492539. Epub 2018 Jul 4. Expert Opin Biol Ther. 2018. PMID: 29936901 Review.
Afatinib and Erlotinib in the treatment of squamous-cell lung cancer.
Tagliamento M, Genova C, Rijavec E, Rossi G, Biello F, Dal Bello MG, Alama A, Coco S, Boccardo S, Grossi F. Tagliamento M, et al. Among authors: biello f. Expert Opin Pharmacother. 2018 Dec;19(18):2055-2062. doi: 10.1080/14656566.2018.1540591. Epub 2018 Nov 3. Expert Opin Pharmacother. 2018. PMID: 30392436 Review.
Comparison Between 18F-FDG PET-Based and CT-Based Criteria in Non-Small Cell Lung Cancer Patients Treated with Nivolumab.
Rossi G, Bauckneht M, Genova C, Rijavec E, Biello F, Mennella S, Dal Bello MG, Cittadini G, Bruzzi P, Piva R, Ceriani V, Sambuceti G, Lopci E, Morbelli S, Grossi F. Rossi G, et al. Among authors: biello f. J Nucl Med. 2020 Jul;61(7):990-998. doi: 10.2967/jnumed.119.233056. Epub 2019 Dec 5. J Nucl Med. 2020. PMID: 31806768
Correlation between B7-H4 and Survival of Non-Small-Cell Lung Cancer Patients Treated with Nivolumab.
Genova C, Boccardo S, Mora M, Rijavec E, Biello F, Rossi G, Tagliamento M, Dal Bello MG, Coco S, Alama A, Vanni I, Barletta G, Bianchi R, Maggioni C, Bruzzi P, Grossi F. Genova C, et al. Among authors: biello f. J Clin Med. 2019 Oct 1;8(10):1566. doi: 10.3390/jcm8101566. J Clin Med. 2019. PMID: 31581482 Free PMC article.
Serial Troponin for Early Detection of Nivolumab Cardiotoxicity in Advanced Non-Small Cell Lung Cancer Patients.
Sarocchi M, Grossi F, Arboscello E, Bellodi A, Genova C, Dal Bello MG, Rijavec E, Barletta G, Rossi G, Biello F, Ghigliotti G, Canepa M, Mussap M, Brunelli C, Spallarossa P. Sarocchi M, et al. Among authors: biello f. Oncologist. 2018 Aug;23(8):936-942. doi: 10.1634/theoncologist.2017-0452. Epub 2018 Mar 22. Oncologist. 2018. PMID: 29567824 Free PMC article.
Advances in treatment of mesothelioma.
Maggioni C, Barletta G, Rijavec E, Biello F, Gualco E, Grossi F. Maggioni C, et al. Among authors: biello f. Expert Opin Pharmacother. 2016 Jun;17(9):1197-205. doi: 10.1080/14656566.2016.1176145. Epub 2016 Apr 21. Expert Opin Pharmacother. 2016. PMID: 27055148 Review.
What is the best pharmacotherapeutic strategy for HER-2 positive breast cancer?
Giannone G, Milani A, Geuna E, Galizia D, Biello F, Montemurro F. Giannone G, et al. Among authors: biello f. Expert Opin Pharmacother. 2019 Jan;20(1):5-9. doi: 10.1080/14656566.2018.1543406. Epub 2018 Nov 6. Expert Opin Pharmacother. 2019. PMID: 30396301 No abstract available.
Nivolumab treatment in advanced lung cancer patient with chronic active hepatitis C and systemic lupus erythematosus.
Tagliamento M, Grossi F, Paolino S, Rijavec E, Genova C, Rossi G, Biello F, De Maria A. Tagliamento M, et al. Among authors: biello f. Immunotherapy. 2019 Jul;11(10):873-879. doi: 10.2217/imt-2019-0025. Epub 2019 Jun 3. Immunotherapy. 2019. PMID: 31156006
Serum PCSK9 levels at the second nivolumab cycle predict overall survival in elderly patients with NSCLC: a pilot study.
Bonaventura A, Grossi F, Carbone F, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, Rijavec E, Dal Bello MG, Rossi G, Biello F, Tagliamento M, Alama A, Coco S, Spallarossa P, Dallegri F, Genova C, Montecucco F. Bonaventura A, et al. Among authors: biello f. Cancer Immunol Immunother. 2019 Aug;68(8):1351-1358. doi: 10.1007/s00262-019-02367-z. Epub 2019 Jul 20. Cancer Immunol Immunother. 2019. PMID: 31327024
Baseline serum levels of osteopontin predict clinical response to treatment with nivolumab in patients with non-small cell lung cancer.
Carbone F, Grossi F, Bonaventura A, Vecchié A, Minetti S, Bardi N, Elia E, Ansaldo AM, Ferrara D, Rijavec E, Dal Bello MG, Biello F, Rossi G, Tagliamento M, Alama A, Coco S, Spallarossa P, Dallegri F, Genova C, Montecucco F. Carbone F, et al. Among authors: biello f. Clin Exp Metastasis. 2019 Oct;36(5):449-456. doi: 10.1007/s10585-019-09984-z. Epub 2019 Aug 2. Clin Exp Metastasis. 2019. PMID: 31376097 Clinical Trial.
41 results
Jump to page
Feedback